Miromatrix to Report First Quarter 2022 Financial Results

Rhea-AI Summary

Miromatrix Medical Inc. (NASDAQ: MIRO) will announce its first quarter 2022 financial results on May 16, 2022, after market close. A conference call is scheduled for the same day at 3:30 PM CT/4:30 PM ET. Miromatrix specializes in bioengineering transplantable organs using proprietary perfusion technology, focusing primarily on human livers and kidneys. The advancements aim to address the shortage of available human organs, potentially enhancing patient outcomes.

Positive

• Focus on bioengineering fully transplantable organs to improve patient lives.
• Proprietary perfusion technology platform may effectively address organ shortage.

Negative

• None.

EDEN PRAIRIE, Minn., April 28, 2022 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients' lives, today announced that the Company will report financial results for the first quarter 2022 after market close on Monday, May 16, 2022. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time.

Individuals interested in listening to the conference call may do so by dialing 877-407-3982 for domestic callers or 201-493-6780 for international callers. Please reference Conference ID: 13729510. To listen to a live webcast, please visit the investor relations section of Miromatrix's website at: https://miromatrix.gcs-web.com/.

About Miromatrix
Miromatrix Medical Inc. is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients' lives. The Company has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. The Company's initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.

Investor Contact
Greg Chodaczek
347-620-7010
ir@miromatrix.com

Media Contact:
press@miromatrix.com

FAQ

When will Miromatrix report its first quarter 2022 financial results?

Miromatrix Medical Inc. will report its first quarter 2022 financial results on May 16, 2022.

What time is the Miromatrix conference call scheduled for?

The Miromatrix conference call is scheduled for 3:30 PM CT / 4:30 PM ET on May 16, 2022.

What is Miromatrix's primary focus in bioengineering?

Miromatrix focuses on bioengineering human livers and kidneys to help address organ shortages.